Does SATRALIZUMAB-MWGE Cause Off label use? 87 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 87 reports of Off label use have been filed in association with SATRALIZUMAB-MWGE. This represents 7.8% of all adverse event reports for SATRALIZUMAB-MWGE.
87
Reports of Off label use with SATRALIZUMAB-MWGE
7.8%
of all SATRALIZUMAB-MWGE reports
2
Deaths
37
Hospitalizations
How Dangerous Is Off label use From SATRALIZUMAB-MWGE?
Of the 87 reports, 2 (2.3%) resulted in death, 37 (42.5%) required hospitalization, and 4 (4.6%) were considered life-threatening.
Is Off label use Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SATRALIZUMAB-MWGE. However, 87 reports have been filed with the FAERS database.
What Other Side Effects Does SATRALIZUMAB-MWGE Cause?
Neuromyelitis optica spectrum disorder (181)
Urinary tract infection (87)
Pneumonia (64)
Covid-19 (47)
No adverse event (47)
Fatigue (41)
Headache (36)
Pain (36)
Arthralgia (31)
Hypoaesthesia (30)
What Other Drugs Cause Off label use?
RITUXIMAB (39,751)
INFLIXIMAB (34,801)
DENOSUMAB (34,612)
METHOTREXATE (24,020)
VEDOLIZUMAB (21,017)
ETANERCEPT (20,178)
TOCILIZUMAB (18,256)
PREDNISONE (17,867)
LENALIDOMIDE (17,017)
ADALIMUMAB (16,417)
Which SATRALIZUMAB-MWGE Alternatives Have Lower Off label use Risk?
SATRALIZUMAB-MWGE vs SAXAGLIPTIN
SATRALIZUMAB-MWGE vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER
SATRALIZUMAB-MWGE vs SCOPOLAMINE
SATRALIZUMAB-MWGE vs SCOPOLAMINE HYDROBROMIDE
SATRALIZUMAB-MWGE vs SEBELIPASE ALFA